by Garth Sundem | May 21, 2019 | Featured, Latest News, Patient Care
D. Ross Camidge, MD, PhD Brigatinib is a next-generation ALK inhibitor that earned FDA approval in 2017 as a second-line therapy after treatment with crizotinib for ALK-positive non-small cell lung cancer. Recently, clinical trial results published in the New England...
by Garth Sundem | Mar 28, 2019 | Latest News, Research
Robert C. Doebele, MD, PhD A study by University of Colorado Cancer Center and Rain Therapeutics, Inc. presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 shows that the clinical-stage drug, tarloxotinib, is active against NRG1-fusion...
by Garth Sundem | Mar 6, 2019 | Featured, Honors, Latest News
James DeGregori, PhD The American Association for Cancer Research (AACR) announced today that in partnership with the Lung Cancer Initiative at Johnson & Johnson, it will fund a major grant led by University of Colorado Cancer Center investigators to pinpoint the...
by Garth Sundem | Feb 11, 2019 | Latest News, Research
Alison Bauer, PhD It is well known that exposure to high-molecular weight polycyclic aromatic hydrocarbons (PAHs) increases cancer risk, leading to regulation of compounds like benzo(a)pyrene (BAP). However, less is known about the health effects of low molecular...
by CU Cancer Center | Jan 3, 2019 | C3 Magazine, Featured, Patient Care
At 32 years old and 33 weeks pregnant, Emily Daniels lived the kind of life that many of us strive to achieve. With a baby boy on the way, a loving husband, a healthy and happy 3-year-old daughter, family and friends close by, a good job, and an active social life,...
